VANCOUVER and TORONTO, Canada (July 10, 2017) — Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term therapeutic approach to prevent hypoglycemia in patients with diabetes, is pleased to announce that Dr. Claude Piché has joined its Board of Directors. As Co-Founder, President and CEO of Locemia Solutions, Dr. Piché led the […]

On March 3, 2017 Rocket Builders announced its 15th annual “Ready to Rocket” lists.  These lists profile British Columbia technology companies that are best positioned to capitalize on the technology sector trends that will lead them to faster growth than their peers. The annual 2017 “Ready to Rocket” lists provide accurate predictions of private companies that will […]

New paper published in The Lancet Diabetes & Endocrinology recommends exercise guidelines for type 1 diabetes patients and healthcare providers. Experts from JDRF, the leading global organization focused on type 1 diabetes (T1D) research, as part of an international team of 21 researchers and clinicians led by York University Professor Michael Riddell, published first-of-its-kind guidelines […]

For Immediate Release                                                                                     BC Ministry of Health Diabetes Awareness Month: diabetes research VICTORIA – Health Minister Terry Lake has issued the following statement for Diabetes Awareness Month: “Diabetes affects over 400,000 British Columbians of all ages. Diabetes Awareness Month is an opportunity to learn more about risk factors for this disease and the impact it has […]

Zucara announced it has received a $525,000 investment from Canadian partners: Accel-Rx Health Sciences Accelerator, The Centre for Drug Research and Development (CDRD) and MaRS Innovation (MI). VANCOUVER and TORONTO, Canada (November 3, 2016) — Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term therapeutic approach to prevent hypoglycemia in patients with […]

This new license is an important step forward in bringing a new drug therapy closer to patients living with diabetes as it will enable us to access a promising lead drug candidate and position us to start clinical trials as early as 2018. VANCOUVER and TORONTO, Canada (October 14, 2016) — Zucara Therapeutics Inc., a […]

VANCOUVER and TORONTO, Canada (September 9, 2016) — Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term therapeutic approach to prevent hypoglycemia in patients with diabetes, has appointed Michael Midmer as its Chief Executive Officer. Midmer has over 15 years of experience in the life sciences, fund management and corporate finance. He […]

The World Health Organization (WHO) has marked April 7, 2016 as World Health Day. The focus of this year’s theme is diabetes. The number of people living with diabetes has almost quadrupled since 1980 to 422 million adults and this number likely to more than double in the next 20 years. For more information on the global call […]

VANCOUVER, BC (February 2, 2016) — The Centre for Drug Research and Development (CDRD) announced today that two of its spin-off companies, Zucara Therapeutics and Sepset Biosciences, have been chosen to present at “Dose of the Valley” in San Francisco on February 9 and 10, 2016. Dose of the Valley is a two-day program organized by the […]